 |
|
|
| |
Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis
|
| |
| |
Reported by Jules Levin
The Liver Meeting (AASLD), Washington, DC, United States, 22 October 2017
Gane E1, Poordad F2, Zadeikis N3, Valdes J3, Lin C-W3, Liu W3, Asatryan A3, Wang S3, Stedman C4, Greenbloom S5, Nguyen T6, Elkhashab M7, Wörns M-A8, Tran A9, Mulkay J-P10, Yu Y3, Pilot-Matias T3, Porcalla A3, Mensa FJ3 1. Auckland Clinical Studies, Auckland, New Zealand; 2. The Texas Liver Institute, University of Texas Health Science Center, San Antonio, Texas, United States; 3. AbbVie Inc., North Chicago, Illinois, United States; 4. Christchurch Hospital and University of Otago, Christchurch, New Zealand ; 5. Toronto Digestive Disease Associates, Toronto, Ontario, Canada; 6. Research and Education, Inc, San Diego, California, United States; 7. Toronto Liver Centre, Toronto, Ontario, Canada; 8. Universitätsmedizin der Johannes-Gutenberg Universität, Mainz, Germany; 9. University Hospital of Nice, Digestive Centre, Nice, France; 10. Hôpital CHU Saint-Pierre, Brussels, Belgium
|
| |
|
|
|
|
|
